BR112019027387A8 - Composições imunogênicas - Google Patents
Composições imunogênicasInfo
- Publication number
- BR112019027387A8 BR112019027387A8 BR112019027387A BR112019027387A BR112019027387A8 BR 112019027387 A8 BR112019027387 A8 BR 112019027387A8 BR 112019027387 A BR112019027387 A BR 112019027387A BR 112019027387 A BR112019027387 A BR 112019027387A BR 112019027387 A8 BR112019027387 A8 BR 112019027387A8
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic compositions
- prevention
- technologies
- treatment
- relates
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010011409 Cross infection Diseases 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/26—Klebsiella (G)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Sustainable Development (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762524315P | 2017-06-23 | 2017-06-23 | |
US62/524,315 | 2017-06-23 | ||
US201862633807P | 2018-02-22 | 2018-02-22 | |
US62/633,807 | 2018-02-22 | ||
PCT/US2018/038907 WO2018237221A1 (en) | 2017-06-23 | 2018-06-22 | IMMUNOGENIC COMPOSITIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112019027387A2 BR112019027387A2 (pt) | 2020-07-14 |
BR112019027387A8 true BR112019027387A8 (pt) | 2022-12-06 |
Family
ID=62916778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019027387A BR112019027387A8 (pt) | 2017-06-23 | 2018-06-22 | Composições imunogênicas |
Country Status (15)
Country | Link |
---|---|
US (2) | US11612647B2 (pt) |
EP (2) | EP3641828B1 (pt) |
JP (2) | JP2020525540A (pt) |
KR (1) | KR20200041311A (pt) |
CN (1) | CN111065417B (pt) |
AU (1) | AU2018290298B2 (pt) |
BR (1) | BR112019027387A8 (pt) |
CA (1) | CA3067587A1 (pt) |
CO (1) | CO2019014647A2 (pt) |
ES (1) | ES2967001T3 (pt) |
IL (1) | IL271603A (pt) |
MX (1) | MX2019015524A (pt) |
PH (1) | PH12019502915A1 (pt) |
SG (1) | SG11201912601RA (pt) |
WO (1) | WO2018237221A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3641828B1 (en) | 2017-06-23 | 2023-11-22 | Affinivax, Inc. | Immunogenic compositions |
WO2019157295A1 (en) * | 2018-02-09 | 2019-08-15 | The Trustees Of Columbia University In The City Of New York | Treating infections using inhibitor of cbb3-type oxidases |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663160A (en) * | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4755381A (en) | 1986-03-27 | 1988-07-05 | Swiss Serum And Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
IL112372A (en) | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
ES2200059T3 (es) | 1995-03-22 | 2004-03-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Produccion de construcciones inmunogenicas usando carbohidratos solubles activados mediante reactivos cianilados organicos. |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
ATE234129T1 (de) | 1996-06-18 | 2003-03-15 | Alza Corp | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
EP0942983B2 (en) | 1996-10-31 | 2014-09-10 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
ATE234649T1 (de) | 1996-12-20 | 2003-04-15 | Alza Corp | Vorrichtung und verfahren zur erhöhung des transdermalen wirkstoffeflusses |
EP0977588B1 (en) | 1997-04-24 | 2004-10-06 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
US6287568B1 (en) | 1997-09-09 | 2001-09-11 | The Trustees Of Columbia University In The City Of New York | Methods relating to immunogenic dextran-protein conjugates |
NZ504894A (en) | 1997-12-02 | 2002-12-20 | Powderject Vaccines Inc | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
EP1117435B1 (en) | 1998-09-30 | 2007-11-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
EP1035137A1 (en) | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US8246945B2 (en) | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US7494653B2 (en) * | 2001-01-26 | 2009-02-24 | Mcw Research Foundation, Inc. | Method and compositions for immunization with the Pseudomonas V antigen |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
EP1404368B1 (en) | 2001-06-07 | 2009-12-09 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
IL159209A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
CN1684707B (zh) | 2002-05-14 | 2012-09-05 | 诺华疫苗和诊断有限公司 | 用于细菌性脑膜炎的粘膜结合疫苗 |
CA2517439C (en) * | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
US20060251675A1 (en) | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
EP2298934A1 (en) | 2003-04-15 | 2011-03-23 | Intercell AG | S. pneumoniae antigens |
EP1626737A2 (en) | 2003-05-07 | 2006-02-22 | Aventis Pasteur, Inc. | Method of enhanced immunogenicity to meningococcal vaccination |
AU2004281634B2 (en) | 2003-09-03 | 2011-01-27 | Dendritherapeutics, Inc. | Multiplex vaccines |
US7556814B2 (en) | 2003-10-23 | 2009-07-07 | Karp Nelson M | Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane |
US20070128183A1 (en) | 2004-04-27 | 2007-06-07 | Intercell Ag | Td antigens |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
ATE512230T1 (de) | 2004-08-18 | 2011-06-15 | Univ Alberta | Proteinherstellungsverfahren unter nutzung von yebf |
FI20041396A0 (fi) | 2004-10-29 | 2004-10-29 | Vesa Pekka Hytoenen | Uudet mikrobiavidiinit |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
JP2008530037A (ja) | 2005-02-11 | 2008-08-07 | エース バイオサイエンシズ エー/エス | 表面に位置したStreptococcuspneumoniaeのポリペプチド |
ATE548051T1 (de) | 2005-04-08 | 2012-03-15 | Wyeth Llc | Multivalente pneumokokken- polysaccharidproteinkonjugatzusammensetzung |
US20090148894A1 (en) | 2005-08-15 | 2009-06-11 | Broedel Sheldon E | Methods for optimizing the secretion of protein in prokaryotes |
EP2308504A3 (en) | 2005-09-01 | 2011-11-30 | Novartis Vaccines and Diagnostics GmbH | Multiple vaccines including serogroup C meningococcus |
JP2009518427A (ja) * | 2005-12-08 | 2009-05-07 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | Invivo細胞表面操作 |
WO2007081583A2 (en) | 2006-01-04 | 2007-07-19 | Children's Medical Center Corporation | Anti-pneumococcal preparations and methods of use |
US7943133B2 (en) | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
US20080032340A1 (en) | 2006-06-09 | 2008-02-07 | University Of Arizona | Peptide motifs for binding avidin or neutravidin |
US8148084B2 (en) | 2006-06-22 | 2012-04-03 | Dana-Farber Cancer Institute, Inc. | Diagnosis of autoimmune disease |
CA2690973A1 (en) | 2006-06-23 | 2007-12-27 | Paul M. Simon | Targeted immune conjugates |
US7452985B2 (en) | 2006-08-17 | 2008-11-18 | Visgeneer, Inc. | Human Ron-related gene variant associated with cancers |
WO2008152448A2 (en) | 2006-12-21 | 2008-12-18 | Emergent Product Development Uk Limited | Streptococcus proteins, and their use in vaccination |
CN100579152C (zh) | 2007-01-29 | 2010-01-06 | 华为技术有限公司 | 一种播放集团彩铃的方法、系统及装置 |
WO2008094986A2 (en) | 2007-01-31 | 2008-08-07 | Dow Global Technologies, Inc. | Bacterial leader sequences for increased expression |
CA2683748C (en) | 2007-04-13 | 2016-02-16 | The Board Of Regents Of The University Of Oklahoma | Mutants of cholesterol-dependent cytolysins and uses thereof |
JP2010531330A (ja) | 2007-06-26 | 2010-09-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US20100168392A1 (en) | 2007-08-10 | 2010-07-01 | Wacker Chemie Ag | Expression of full length igg and secretion into the culture medium of prokaryotic cells |
US8840906B2 (en) | 2007-08-31 | 2014-09-23 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung disease and conditions |
CA2748149C (en) | 2008-12-24 | 2018-03-06 | Netherlands Vaccine Institute | Modified steptococcus pneumonia pneumolysin (ply) polypeptides |
EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
WO2011008548A1 (en) | 2009-06-29 | 2011-01-20 | Genocea Biosciences, Inc. | Vaccines and compositions against streptococcus pneumoniae |
CN101797381B (zh) | 2010-01-29 | 2012-05-23 | 中国人民解放军第三军医大学 | 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用 |
CN102834112B (zh) | 2010-02-22 | 2016-02-24 | 流体科技公司 | 多糖颗粒疫苗 |
US20130115230A1 (en) | 2010-04-30 | 2013-05-09 | Augmenta Biologicals, Llc | Delivery proteins |
WO2012155053A1 (en) * | 2011-05-11 | 2012-11-15 | Children's Medical Center Corporation | Modified biotin-binding protein, fusion proteins thereof and applications |
WO2014018904A1 (en) | 2012-07-26 | 2014-01-30 | Genocea Biosciences, Inc. | Fused antigen vaccines and compositions against streptococcus pneumoniae |
WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
LT3131577T (lt) * | 2014-04-17 | 2020-07-27 | Glaxosmithkline Biologicals S.A. | Modifikuotos ląstelės-šeimininkės ir jų naudojimas |
EP3193918A4 (en) * | 2014-09-18 | 2018-06-20 | University of Maryland, Baltimore | Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections |
US20170073397A1 (en) * | 2015-08-24 | 2017-03-16 | Medimmune, Llc | MrkA Polypeptides, Antibodies, and Uses Thereof |
CA3061709A1 (en) | 2017-03-28 | 2018-10-04 | The Children's Medical Center Corporation | A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
EP3641828B1 (en) | 2017-06-23 | 2023-11-22 | Affinivax, Inc. | Immunogenic compositions |
BR112021004193A2 (pt) | 2018-09-12 | 2021-05-25 | Affinivax, Inc. | vacinas pneumocócicas multivalentes |
-
2018
- 2018-06-22 EP EP18740975.0A patent/EP3641828B1/en active Active
- 2018-06-22 CN CN201880054606.XA patent/CN111065417B/zh active Active
- 2018-06-22 KR KR1020207002336A patent/KR20200041311A/ko not_active Application Discontinuation
- 2018-06-22 AU AU2018290298A patent/AU2018290298B2/en active Active
- 2018-06-22 ES ES18740975T patent/ES2967001T3/es active Active
- 2018-06-22 JP JP2020520197A patent/JP2020525540A/ja active Pending
- 2018-06-22 BR BR112019027387A patent/BR112019027387A8/pt active Search and Examination
- 2018-06-22 MX MX2019015524A patent/MX2019015524A/es unknown
- 2018-06-22 WO PCT/US2018/038907 patent/WO2018237221A1/en active Application Filing
- 2018-06-22 EP EP23207415.3A patent/EP4327876A3/en active Pending
- 2018-06-22 SG SG11201912601RA patent/SG11201912601RA/en unknown
- 2018-06-22 US US16/625,468 patent/US11612647B2/en active Active
- 2018-06-22 CA CA3067587A patent/CA3067587A1/en active Pending
-
2019
- 2019-12-19 IL IL271603A patent/IL271603A/en unknown
- 2019-12-20 PH PH12019502915A patent/PH12019502915A1/en unknown
- 2019-12-23 CO CONC2019/0014647A patent/CO2019014647A2/es unknown
-
2023
- 2023-02-03 US US18/105,791 patent/US20230414740A1/en active Pending
- 2023-11-28 JP JP2023200353A patent/JP2024028769A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3641828B1 (en) | 2023-11-22 |
RU2020102449A3 (pt) | 2022-03-24 |
CN111065417B (zh) | 2024-04-19 |
EP3641828A1 (en) | 2020-04-29 |
JP2020525540A (ja) | 2020-08-27 |
MX2019015524A (es) | 2020-09-10 |
SG11201912601RA (en) | 2020-01-30 |
CN111065417A (zh) | 2020-04-24 |
BR112019027387A2 (pt) | 2020-07-14 |
US20230414740A1 (en) | 2023-12-28 |
ES2967001T3 (es) | 2024-04-25 |
US20220072118A1 (en) | 2022-03-10 |
IL271603A (en) | 2020-02-27 |
WO2018237221A1 (en) | 2018-12-27 |
AU2018290298A2 (en) | 2020-02-27 |
PH12019502915A1 (en) | 2020-09-28 |
EP4327876A3 (en) | 2024-05-22 |
KR20200041311A (ko) | 2020-04-21 |
CA3067587A1 (en) | 2018-12-27 |
AU2018290298A1 (en) | 2020-01-16 |
EP4327876A2 (en) | 2024-02-28 |
CO2019014647A2 (es) | 2020-04-24 |
AU2018290298B2 (en) | 2024-03-28 |
RU2020102449A (ru) | 2021-07-26 |
US11612647B2 (en) | 2023-03-28 |
JP2024028769A (ja) | 2024-03-05 |
TW201925222A (zh) | 2019-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
CO2018010459A2 (es) | Composiciones que comprenden cepas bacterianas | |
CL2018001368A1 (es) | Composiciones que comprenden cepas bacterianas | |
MD3804737T2 (ro) | Compoziții care conțin tulpini bacteriene | |
CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
MX2023003461A (es) | Tratamiento de infeccion por clostridium difficile. | |
CO2017013443A2 (es) | Composiciones que comprenden cepas bacterianas del género blautia | |
PE20180266A1 (es) | Composiciones que comprenden cepas bacterianas | |
BR112018010464A2 (pt) | formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas | |
BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
MD3600363T2 (ro) | Compoziții cuprinzând tulpini bacteriene | |
MD3638271T2 (ro) | Compoziții cuprizând tulpini bacteriene | |
BR112017022391A2 (pt) | composições e métodos para a fiscalização de câncer de próstata | |
ECSP17074919A (es) | Piroglutamato de vortioxetina | |
BR112017005272A2 (pt) | uso de cisteamina no tratamento de infecções causadas por leveduras/bolores | |
UY36801A (es) | PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM | |
BR112019027387A8 (pt) | Composições imunogênicas | |
BR112019024249A2 (pt) | Métodos e tratamento de trauma | |
BR112017005993A2 (pt) | derivados de peptídeo inovadores e usos dos mesmos | |
BR112017005134A2 (pt) | tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B25A | Requested transfer of rights approved |
Owner name: UNIVERSITY OF MARYLAND, BALTIMORE (US) ; AFFINIVAX, INC. (US) ; ASTELLAS US LLC (US) |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: UNIVERSITY OF MARYLAND, BALTIMORE (US) ; AFFINIVAX, INC. (US) ; ASTELLAS US LLC (US) |
|
B25A | Requested transfer of rights approved |
Owner name: UNIVERSITY OF MARYLAND, BALTIMORE (US) ; AFFINIVAX, INC. (US) |